ANIKA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.59 USD | 0.00% |
|
+7.90% | +21.76% |
| Mar. 14 | Barrington Ups Price Target on Anika Therapeutics to $37 From $29, Keeps Outperform Rating | MT |
| Mar. 13 | Transcript : Anika Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- Low profitability weakens the company.
- The company is highly valued given the cash flows generated by its activity.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +21.76% | 405M | C | ||
| +1.45% | 40.51B | A- | ||
| -15.94% | 31.67B | B- | ||
| +52.66% | 24.62B | A | ||
| -14.50% | 15.65B | C | ||
| -14.38% | 12.07B | B- | ||
| -9.12% | 11.97B | D+ | ||
| -42.56% | 11.61B | B | ||
| +4.87% | 8.81B | B+ | ||
| -4.33% | 8.5B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ANIK Stock
- Ratings Anika Therapeutics, Inc.
